BLA 103951 · Amgen
Aranesp
Darbepoetin Alfa · Subcutaneous, Intravenous · Erythropoiesis-stimulating Agent
NovelLast checked: Nov 20, 2026Latest source record: Apr 30, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2001
Sep 17, 2001
Approved uses
8
Original approval plus efficacy supplements
Registered trials
216
100 Phase 3, 10 recruiting
FAERS reports
54,075
48,342 serious, 20,052 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: ESAs INCREASE THE RISK OF DEATH, MYOCARDIAL INFARCTION, STROKE, VENOUS THROMBOEMBOLISM, THROMBOSIS OF VASCULAR ACCESS AND TUMOR PROGRESSION OR RECURRENCE Chronic Kidney Disease: In controlled trials, patients experienced greater risks for death, serious adverse cardiovascular reactions, and stroke when administered erythropoiesis -stimulating agents (ESAs) to target a hemoglobin level of greater than 11 g/dL [ see Warnings and Precautions ( 5.1 )] . No trial has identified a hemoglobin target level, Aranesp dose, or dosing strategy that does not increase these risks [see Dosage and Administration ( 2.2 )] . Use the lowest Aranesp dose sufficient to reduce the need for red blood cell (RBC) transfusions [see Warnings and Precautions ( 5.1 )] . Cancer: ESAs shortened overall survival and/or increased the risk of tumor progression or recurrence in clinical studies of patients with...
What it is approved for
From the label in effect Jul 7, 2026.
Aranesp is an erythropoiesis-stimulating agent (ESA) indicated for the treatment of anemia due to: Chronic Kidney Disease (CKD) in patients on dialysis and patients not on dialysis ( 1.1 ). The effects of concomitant myelosuppressive chemotherapy, and upon initiation, there is a minimum of two additional months of planned chemotherapy ( 1.2 ). Limitations of Use Aranesp has not been shown to improve quality of life, fatigue, or patient well-being ( 1.3 ). Aranesp is not indicated for use: In patients with cancer receiving hormonal agents, biologic products, or radiotherapy, unless also receiving concomitant myelosuppressive chemotherapy ( 1.3 ). In patients with cancer receiving myelosuppressive chemotherapy when the anticipated outcome is cure ( 1.3 ). In patients with cancer receiving myelosuppressive chemotherapy in whom the anemia can be managed by transfusion ( 1.3 ). As a substitute for RBC transfusions in patients who require immediate correction of anemia ( 1.3 ). 1.1 Anemia Due to Chronic Kidney Disease Aranesp is indicated for the treatment of anemia due to chronic kidney disease (CKD), including patients on dialysis and patients not on dialysis. 1.2 Anemia Due to Chemotherapy in Patients with Cancer Aranesp is indicated for the treatment of anemia in patients with non-myeloid malignancies where anemia is due to the effect of concomitant myelosuppressive chemotherapy, and upon initiation, there is a minimum of two additional months of planned chemotherapy. 1.3 Limitations of Use Aranesp has not been shown to improve quality of life, fatigue, or patient well-being. Aranesp is not indicated for use: • In patients with cancer receiving hormonal agents, biologic products, or radiotherapy, unless also receiving concomitant myelosuppressive chemotherapy. • In...
Mechanism: Aranesp stimulates erythropoiesis by the same mechanism as endogenous erythropoietin.
Therapeutic areas: Hematology and blood cancers
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jan 30, 2019 Supplement 5378 · Efficacy · priority review LabelLetterMedication Guide
- Jul 23, 2015 Supplement 5363 · Efficacy LabelPediatric Medical ReviewPediatric Statistical Review
- Jun 24, 2011 Supplement 5173 · Efficacy LetterLabelReview
- May 5, 2008 Supplement 5111 · Efficacy
- Mar 23, 2006 Supplement 5097 · Efficacy LabelLetter
- Dec 15, 2005 Supplement 5088 · Efficacy LabelLetter
- Jul 19, 2002 Supplement 5001 · Efficacy LabelPatient Package InsertReview
- Sep 17, 2001 Original approval · Type 1 - New Molecular Entity NovelLabelReviewLetter
10 products under this application
- ARANESP · DARBEPOETIN ALFA 100UG/ML · VIAL, SUBCUTANEOUS · Prescription
- ARANESP · DARBEPOETIN ALFA 40UG/ML · VIAL, SUBCUTANEOUS · Prescription
- ARANESP · DARBEPOETIN ALFA 200UG/ML · VIAL, INTRAVENOUS · Prescription
- ARANESP · DARBEPOETIN ALFA 60UG/ML · VIAL, INTRAVENOUS · Prescription
- ARANESP · DARBEPOETIN ALFA 25UG/ML · VIAL, INTRAVENOUS · Prescription
- ARANESP · DARBEPOETIN ALFA 60UG/ML · VIAL, SUBCUTANEOUS · Prescription
- ARANESP · DARBEPOETIN ALFA 25UG/ML · VIAL, SUBCUTANEOUS · Prescription
- ARANESP · DARBEPOETIN ALFA 100UG/ML · VIAL, INTRAVENOUS · Prescription
- ARANESP · DARBEPOETIN ALFA 200UG/ML · VIAL, SUBCUTANEOUS · Prescription
- ARANESP · DARBEPOETIN ALFA 40UG/ML · VIAL, INTRAVENOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Darbepoetin Alfa" as an intervention, any sponsor and status, largest first.
- Trial to Reduce Cardiovascular Events With Aranesp® Therapy (TREAT)Pivotal-lookingCompleted
AmgenAmgen (AMGN)
NCT00093015 · 4,038 participants · Start Aug 1, 2004 · Primary completion Mar 1, 2009
Drug: Placebo; darbepoetin alfa · For: Kidney Disease; Diabetes Mellitus; Anemia
- Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND)Pivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT02876835 · 3,872 participants · Start Sep 27, 2016 · Primary completion Apr 19, 2021
Drug: Daprodustat; Darbepoetin alfa and 2 more · For: Anaemia
Sites: Andalusia, Alabama; Birmingham, Alabama; Huntsville, Alabama · 574 sites in all
- Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Participants With Dialysis-dependent Chronic Kidney Disease (DD-CKD)Pivotal-lookingCompleted
Akebia TherapeuticsIndustry
NCT02892149 · 3,554 participants · Start Aug 2016 · Primary completion Jan 16, 2020
Drug: Vadadustat; Darbepoetin alfa · For: Anemia; Dialysis-Dependent Chronic Kidney Disease
Sites: Huntsville, Alabama; Mesa, Arizona; Pine Bluff, Arkansas · 278 sites in all
- Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Dialysis (ASCEND-D)Pivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT02879305 · 2,964 participants · Start Sep 28, 2016 · Primary completion Nov 9, 2020
Drug: Daprodustat; rhEPO and 2 more · For: Anaemia; Aspergillosis, Allergic Bronchopulmonary
Sites: Huntsville, Alabama; Pine Bluff, Arkansas; Anaheim, California · 462 sites in all
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT00773513 · 2,825 participants · Start Dec 12, 2008 · Primary completion Jul 27, 2017
Drug: Darbepoetin Alfa; Epoetin Alfa and 2 more · For: Chronic Renal Anemia
Sites: Buenos Aires, Argentina; CABA, Argentina; Gosford, Australia · 196 sites in all
- Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving ChemotherapyPivotal-lookingTerminated
AmgenAmgen (AMGN)
NCT00858364 · 2,549 participants · Start Jul 17, 2009 · Primary completion Jun 7, 2017
Drug: Darbepoetin alfa; Placebo · For: Non-Small Cell Lung Cancer; Anemia; Cancer and 1 more
Sites: Anniston, Alabama; Birmingham, Alabama; Anchorage, Alaska · 566 sites in all
- A Study to Assess Symptom Burden in Subjects With Nonmyeloid Malignancies Receiving Chemotherapy and Aranesp®Pivotal-lookingCompleted
AmgenAmgen (AMGN)
NCT00117117 · 2,423 participants · Start Sep 2002
Drug: Aranesp · For: Anemia
- RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure TrialPivotal-lookingCompleted
AmgenAmgen (AMGN)
NCT00358215 · 2,278 participants · Start Jun 1, 2006 · Primary completion Oct 11, 2012
Drug: Darbepoetin alfa; Placebo · For: Heart Failure; Anemia; Cardiovascular Disease and 2 more
Sites: Birmingham, Alabama; Huntsville, Alabama; Mobile, Alabama · 754 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- death16,296
- hospitalisation6,211
- off label use2,624
- anaemia2,197
- haemoglobin decreased1,664
- product storage error1,623
- pneumonia1,504
- fatigue1,491
- dyspnoea1,458
- diarrhoea1,339
- nausea1,309
- fall1,218
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 499 |
| 2005 | 637 |
| 2006 | 935 |
| 2007 | 935 |
| 2008 | 860 |
| 2009 | 914 |
| 2010 | 935 |
| 2011 | 1,073 |
| 2012 | 1,680 |
| 2013 | 1,536 |
| 2014 | 5,752 |
| 2015 | 6,451 |
| 2016 | 6,847 |
| 2017 | 7,062 |
| 2018 | 4,413 |
| 2019 | 1,520 |
| 2020 | 1,681 |
| 2021 | 1,595 |
| 2022 | 1,610 |
| 2023 | 2,363 |
| 2024 | 1,996 |
| 2025 | 1,434 |
| 2026 | 1,347 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Aranesp (Darbepoetin Alfa In Polysorbat)
2024 spending
$62.5M
Beneficiaries
6,472
27,006 claims
Per beneficiary
$9,663
$2,556.45 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $53,121,165 |
| 2021 | $50,716,091 |
| 2022 | $54,796,645 |
| 2023 | $59,909,953 |
| 2024 | $62,541,381 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Daprodustat for the Treatment of Anemia in Patients Undergoing Dialysis.
Singh AK, Carroll K, Perkovic V, et al. · N Engl J Med 2021 · Clinical Trial, Phase III, Comparative Study
- Daprodustat for the Treatment of Anemia in Patients Not Undergoing Dialysis.
Singh AK, Carroll K, McMurray JJV, et al. · N Engl J Med 2021 · Clinical Trial, Phase III, Comparative Study
- Safety and Efficacy of Vadadustat for Anemia in Patients Undergoing Dialysis.
Eckardt KU, Agarwal R, Aswad A, et al. · N Engl J Med 2021 · Clinical Trial, Phase III, Comparative Study
- Vadadustat in Patients with Anemia and Non-Dialysis-Dependent CKD.
Chertow GM, Pergola PE, Farag YMK, et al. · N Engl J Med 2021 · Clinical Trial, Phase III, Comparative Study
- Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis.
Chung EY, Palmer SC, Saglimbene VM, et al. · Cochrane Database Syst Rev 2023 · Systematic Review, Research Support, Non-U.S. Gov't
- Efficacy and safety of daprodustat versus darbepoetin alfa in the treatment of anemia in chronic renal failure: Systematic review and meta-analysis of randomized controlled trials.
Pang S, Wang Z, Fu Y, et al. · J Pharmacol Sci 2025 · Meta-Analysis, Systematic Review
Sponsor: Amgen
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.